Latest Attention-deficit hyperactivity disorder management Stories
Following is a summary of the key Shire scientific presentations.
HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today.
NEW YORK, Sept.
WALTHAM, Mass., Sept.
Low levels of dopamine markers may underlie symptoms; implications for treatment.
TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S.
PHILADELPHIA, September 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.
Parents should be aware of certain behavioral symptoms in the classroom that might indicate their child should be screened for attention deficit disorder and attention deficit hyperactivity disorder, an expert at Baylor College of Medicine
- A trick or prank.